Algorithm for Discovering Genetic Interactions in Genome-Wide Association Studies (BridGE)

Technology No. 20160109
IP Status: Pending Foreign Patent; Application #: 3017736

Bridging Gene Sets with Epistasis

BridGE (Bridging Gene Sets with Epistasis) is an innovative computational method that explicitly searches for disease-specific genetic interactions between single nucleotide polymorphisms (SNPs) in Genome-wide Association Studies (GWAS) data. The algorithm searches for larger, non-random structures of SNP-SNP interactions, guided by established sets of genes belonging to characterized pathways or gene modules. The concept was derived from extensive analysis of genetic interaction networks in yeast, which showed that genetic interactions tend to cluster between functionally compensatory pathways. If several SNPs interact between genes coding for proteins/pathways with redundant functions, the likelihood of obtaining statistical significance by searching for larger clusters of SNP-SNP interactions is much greater than if individual SNP interactions were considered separately. Applying BridGE broadly, significant interactions were discovered in Parkinson’s disease, schizophrenia, hypertension, prostate cancer, type 2 diabetes and breast cancer.

Maps Complex Genetic Networks Underlying Human Disease

Detecting genetic interactions is important for fully characterizing heritability of complex diseases within Genome Wide Association Studies (GWAS). Current methods for detecting such genetic interactions are inaccurate, lacking statistical power and failing to reliably detect genetic interactions important for characterizing the heritability of complex diseases. By explicitly searching GWAS data for disease-specific genetic interactions between pathways, BridGE identifies large, non-random clusters that tend to contain genetic interactions. The technology has the potential to transform interpretation of human genome data and expand the therapeutic target space for complex genetic diseases.

BENEFITS AND FEATURES:

  • Analyzes GWAS, whole genome sequencing (WGS), and whole exome sequencing (WES) data
  • Identifies large, non-random clusters that contain genetic interactions
  • Likely more reliable than existing detection of genetic interactions
  • Identifies genetic interactions (SNPs) between genes within specific signaling pathways
  • May help understand genetic risk or protective factors for particular diseases
  • May help understand effectiveness of therapeutic strategies (e.g. pharmacological agents) in treating various conditions
  • Additional features as needed

APPLICATIONS:

  • Pharmacogenomics
  • Drug discovery and testing
  • Bioinformatics
  • Genome Wide Association Studies 
  • Whole Genome Sequencing
  • Whole Exome Sequencing
  • Assess genetic risk or protective factors for particular diseases
  • Evaluate effectiveness of therapeutic strategies (e.g. pharmacological agents)
  • Genetically modified foods and organisms
  • Methods for generating genetic information (Next Generation Sequencing (NGS), BioChips)
  • Personalized medicine

Academic License

The Academic License is available for teaching and non-profit research.

Please contact us if you are interested in licensing the technology for commercial purposes.


Researchers
Chad Myers, PhD
Associate Professor, Computer Science
External Link (www.cs.umn.edu)
Vipin Kumar, PhD
Professor, Computer Science
External Link (www-users.cs.umn.edu)

Publications
Discovering genetic interactions bridging pathways in genome-wide association studies
bioRxiv, August 30, 2017
Pathway-based discovery of genetic interactions in breast cancer
PLOS Genetics, Sept 28, 2017
  • swap_vertical_circlecloud_downloadSupporting documents (0)
    Additional files may be available once you've completed the transaction for this product. If you've already done so, please log into your account and visit My account / Downloads section to view them.
Bridging Gene Sets with Epistasis Software (BridGE) – Academic License

Term: perpetual

Price per user:
$0.00 excl. TAX

Questions about this technology?